Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 245 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Needle-Syringe Clear all

Conditions: HIV Infections
Interventions: PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Ankle Fracture
Interventions: Ankle Aspiration, Ankle aspiration Standard Anterolateral; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type I Diabetes
Interventions: NNC0361-0041, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 16
States / cities: Orange, California • San Francisco, California • Stanford, California + 13 more

Conditions: Shoulder Impingement Syndrome
Interventions: Manual Physical Therapy, Corticosteroid Injection; Procedure
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Influenza
Interventions: VRC-FLUNPF0103-00-VP (H10ssF-6473); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, Substance Use Disorders, Substance Abuse, Intravenous
Interventions: elbasvir-grazoprevir (50 mg/100 mg); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Healthy
Interventions: Harvard Apparatus syringe pump; Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Influenza, Human
Interventions: Influenza Vaccine; Biological
Lead sponsor: PharmaJet, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 985 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Breast Abscess
Interventions: Standard of care breast abscess drainage, Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser illumination, Photodynamic therapy; Procedure · Drug · Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Leber Hereditary Optic Neuropathy (LHON)
Interventions: NR082 Injection, Injection needle; Drug · Device
Lead sponsor: Neurophth Therapeutics Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Palo Alto, California • Aurora, Colorado • Philadelphia, Pennsylvania

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions: Faricimab PFS Configuration; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Mesa, Arizona • Phoenix, Arizona

Conditions: Diabetic Foot Infection
Interventions: TP-102, Placebo; Biological · Other
Lead sponsor: Technophage, SA; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Webster, Texas

Conditions: Type1diabetes, Insulitis, Pancreas Inflamed
Interventions: Definity Suspension for Injection; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Nasolabial Folds, Wrinkles
Interventions: TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines; Device
Lead sponsor: Teoxane SA; Industry
Eligibility: 22 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Birmingham, Alabama • Beverly Hills, California • Santa Monica, California + 2 more

Conditions: Prevention of Zika Infection, Zika-Specific Immune Response
Interventions: VRC-ZKADNA090-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Interventions: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL); Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Anaheim, California • DeLand, Florida • Miami, Florida + 2 more

Conditions: Healthy Volunteers
Interventions: Etrolizumab, Auto-Injector (AI), Prefilled Syringe With Needle Safety Device (PFS-NSD); Drug · Device
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more

Conditions: Nail Diseases
Interventions: Platelet-rich plasma, Platelet-poor plasma; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Lipoma
Interventions: Cooled Sodium Chloride Injection, Warmed Sodium Chloride Injection; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Healthy
Interventions: Lebrikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: Macular Edema, Branch Retinal Vein Occlusion
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more

Conditions: Sarcoma,Soft Tissue
Interventions: Tirzepatide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: h-Patch; Device
Lead sponsor: Valeritas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hysterectomy
Interventions: Bupivacaine Hydrochloride 0.25% Injection Solution; Drug
Lead sponsor: Jon I. Einarsson; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

Aspiration for Pain Relief Following Ankle Fracture

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Physical Therapy Versus Steroid Injection for Shoulder Impingement Syndrome

Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults

Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care

A Study of Subcutaneous Injection in Healthy Participants

Inactivated Influenza Via Jet Injection

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

Pancreas Ultrasound Imaging in type1 Diabetes

TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds

VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults

Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)

Use of Platelet-rich Plasma (PRP) Therapy in Patients With Brittle Nail Syndrome

Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study

Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device

RCT Superior Hypogastric Block During LH